ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 9,470 shares, an increase of 66.4% from the October 15th total of 5,692 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average trading volume of 28,464 shares, the days-to-cover ratio is currently 0.3 days.
Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF
Several hedge funds and other institutional investors have recently modified their holdings of SBIO. Steward Partners Investment Advisory LLC grew its stake in ALPS Medical Breakthroughs ETF by 9.3% during the third quarter. Steward Partners Investment Advisory LLC now owns 5,976 shares of the company’s stock worth $348,000 after purchasing an additional 508 shares during the period. HighTower Advisors LLC bought a new position in ALPS Medical Breakthroughs ETF during the 3rd quarter valued at approximately $2,384,000. Phoenix Wealth Advisors lifted its position in ALPS Medical Breakthroughs ETF by 33.6% in the 3rd quarter. Phoenix Wealth Advisors now owns 11,212 shares of the company’s stock valued at $654,000 after acquiring an additional 2,822 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in ALPS Medical Breakthroughs ETF in the 3rd quarter worth approximately $688,000. Finally, NTV Asset Management LLC lifted its holdings in ALPS Medical Breakthroughs ETF by 1.2% during the 3rd quarter. NTV Asset Management LLC now owns 17,283 shares of the company’s stock valued at $1,008,000 after buying an additional 200 shares in the last quarter.
ALPS Medical Breakthroughs ETF Stock Performance
Shares of NYSEARCA:SBIO traded down $1.76 on Monday, hitting $53.87. The stock had a trading volume of 18,349 shares, compared to its average volume of 37,176. ALPS Medical Breakthroughs ETF has a twelve month low of $45.65 and a twelve month high of $70.85. The firm’s 50 day moving average price is $57.31 and its 200-day moving average price is $57.19. The company has a market capitalization of $180.46 million, a price-to-earnings ratio of 6.73 and a beta of 0.79.
About ALPS Medical Breakthroughs ETF
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Read More
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
